Search
Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma
- Nammi Therapeutics
- Nov 8, 2024
- 1 min read
Updated: Nov 14, 2024
Nammi Therapeutics, Inc., a clinical stage immuno-oncology company with a diverse pipeline created with the Masked-Immunocytokine (MIC) and Nammisome platforms, announces dosing of the first patient in the first in human Phase 1 trial (NCT06582017)
Recent Posts
See AllNammi Therapeutics announces a $1M investment commitment by the Myeloma Investment Fund in a $30M Series B financing round prior to the...
Nammi Therapeutics was featured in the Los Angeles Business Journal. The article featured an interview with David Stover, President and...
Amgen and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticker in...
Comments